Search results for the GEO ID: GSE16464
(Click on the check boxes provided under "Select for analysis", to initiate grouping)
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down)
GSM ID
GPL ID
Select for analysis
Title
Source name
Description
Characteristics
GSM413840
GPL570
monolayer chondrocytes from normal donor 1 human subcultured chondrocytes (passage 2) from normal donors disease group: normal cell type: chondrocytes cell culture: monolayer ND_1_Chon_Med_P2_133P human chondrocytes cultured in DMEM/F12 supplemented with L-ascorbic acid (0.025 mg/ml, gentamicin sulphate (50 mg/l), amphotericin B (250 µg/ml) and L-glutamine (2 mM; Gibco) and 10% human serum for 2 passages; normal donor group (46-52 years, no pre-existing history of OA, macroscopically healthy cartilage, undergoing ACT treatment) human chondrocytes isolated from the non-weight bearing area of the knee cartilage of patients undergoing ACT treatment, subcultured up to passage 2 (primary cells = passage 0), monolayer culture from normal donor 1
GSM413841
GPL570
monolayer chondrocytes from normal donor 2 human subcultured chondrocytes (passage 2) from normal donors disease group: normal cell type: chondrocytes cell culture: monolayer ND_2_Chon_Med_P2_133P human chondrocytes cultured in DMEM/F12 supplemented with L-ascorbic acid (0.025 mg/ml, gentamicin sulphate (50 mg/l), amphotericin B (250 µg/ml) and L-glutamine (2 mM; Gibco) and 10% human serum for 2 passages; normal donor group (46-52 years, no pre-existing history of OA, macroscopically healthy cartilage, undergoing ACT treatment) human chondrocytes isolated from the non-weight bearing area of the knee cartilage of patients undergoing ACT treatment, subcultured up to passage 2 (primary cells = passage 0), monolayer culture from normal donor 2
GSM413842
GPL570
monolayer chondrocytes from normal donor 3 human subcultured chondrocytes (passage 2) from normal donors disease group: normal cell type: chondrocytes cell culture: monolayer ND_3_Chon_Med_P2_133P human chondrocytes cultured in DMEM/F12 supplemented with L-ascorbic acid (0.025 mg/ml, gentamicin sulphate (50 mg/l), amphotericin B (250 µg/ml) and L-glutamine (2 mM; Gibco) and 10% human serum for 2 passages; normal donor group (46-52 years, no pre-existing history of OA, macroscopically healthy cartilage, undergoing ACT treatment) human chondrocytes isolated from the non-weight bearing area of the knee cartilage of patients undergoing ACT treatment, subcultured up to passage 2 (primary cells = passage 0), monolayer culture from normal donor 3
GSM413843
GPL570
monolayer chondrocytes from OA donor 1 human subcultured chondrocytes (passage 2) from OA donors disease group: osteoarthritis cell type: chondrocytes cell culture: monolayer OA_1_Chon_Med_P2_133P human chondrocytes cultured in DMEM/F12 supplemented with L-ascorbic acid (0.025 mg/ml, gentamicin sulphate (50 mg/l), amphotericin B (250 µg/ml) and L-glutamine (2 mM; Gibco) and 10% human serum for 2 passages; OA donor group (60-64 years, symptoms of severe OA, undergoing total knee replacement, radiological evidence of OA, OA grade 2-3 according to Ahlbäck, and exhibiting a Mankin score above 3) human chondrocytes isolated from cartilage biopsies from patients undergoing total knee replacement, subcultured up to passage 2 (primary cells = passage 0), monolayer culture from OA donor 1
GSM413844
GPL570
monolayer chondrocytes from OA donor 2 human subcultured chondrocytes (passage 2) from OA donors disease group: osteoarthritis cell type: chondrocytes cell culture: monolayer OA_2_Chon_Med_P2_133P human chondrocytes cultured in DMEM/F12 supplemented with L-ascorbic acid (0.025 mg/ml, gentamicin sulphate (50 mg/l), amphotericin B (250 µg/ml) and L-glutamine (2 mM; Gibco) and 10% human serum for 2 passages, OA donor group (60-64 years, symptoms of severe OA, undergoing total knee replacement, radiological evidence of OA, OA grade 2-3 according to Ahlbäck, and exhibiting a Mankin score above 3) human chondrocytes isolated from cartilage biopsies from patients undergoing total knee replacement, subcultured up to passage 2 (primary cells = passage 0), monolayer culture from OA donor 2
GSM413845
GPL570
monolayer chondrocytes from OA donor 3 human subcultured chondrocytes (passage 2) from OA donors disease group: osteoarthritis cell type: chondrocytes cell culture: monolayer OA_3_Chon_Med_P2_133P human chondrocytes cultured in DMEM/F12 supplemented with L-ascorbic acid (0.025 mg/ml, gentamicin sulphate (50 mg/l), amphotericin B (250 µg/ml) and L-glutamine (2 mM; Gibco) and 10% human serum for 2 passages; OA donor group (60-64 years, symptoms of severe OA, undergoing total knee replacement, radiological evidence of OA, OA grade 2-3 according to Ahlbäck, and exhibiting a Mankin score above 3) human chondrocytes isolated from cartilage biopsies from patients undergoing total knee replacement, subcultured up to passage 2 (primary cells = passage 0), monolayer culture from OA donor 3
GSM413846
GPL570
3D-cultured chondrocytes from normal donor 1 human subcultured chondrocytes (passage 2) from normal donors maintained for 14 days in scaffold culture disease group: normal cell type: chondrocytes cell culture: 3-D ND_1_Chon_CHyaff_D14_133P human chondrocytes cultured in DMEM/F12 supplemented with L-ascorbic acid (0.025 mg/ml, gentamicin sulphate (50 mg/l), amphotericin B (250 µg/ml) and L-glutamine (2 mM; Gibco) and 10% human serum for 2 passages, 3D culture in Hyaff-11 scaffolds for 14 days maintained in DMEM high glucose supplemented with 5.0 µg/ml linoleic acid, insulin-transferrin-selenium-G, 1.0 mg/ml human serum albumin, 10 ng/ml transforming growth factor beta 1 (TGF-b1), 10-7 M dexamethasone , 14 µg/ml L-ascorbic acid and 1% penicillin-streptomycin; normal donor group (46-52 years, no pre-existing history of OA, macroscopically healthy cartilage, undergoing ACT treatment) human chondrocytes isolated from non-weight bearing area of the knee cartilage of patients undergoing ACT treatment, subcultured up to passage 2 (primary cells = passage 0), seeded onto hyaff-11 scaffold, maintained for 14 days in the presence of TGFbeta 1, chondrocytes obtained from normal donor 1
GSM413847
GPL570
3D-cultured chondrocytes from normal donor 2 human subcultured chondrocytes (passage 2) from normal donors maintained for 14 days in scaffold culture disease group: normal cell type: chondrocytes cell culture: 3-D ND_2_Chon_CHyaff_D14_133P human chondrocytes cultured in DMEM/F12 supplemented with L-ascorbic acid (0.025 mg/ml, gentamicin sulphate (50 mg/l), amphotericin B (250 µg/ml) and L-glutamine (2 mM; Gibco) and 10% human serum for 2 passages, 3D culture in Hyaff-11 scaffolds for 14 days maintained in DMEM high glucose supplemented with 5.0 µg/ml linoleic acid, insulin-transferrin-selenium-G, 1.0 mg/ml human serum albumin, 10 ng/ml transforming growth factor beta 1 (TGF-b1), 10-7 M dexamethasone , 14 µg/ml L-ascorbic acid and 1% penicillin-streptomycin; normal donor group (46-52 years, no pre-existing history of OA, macroscopically healthy cartilage, undergoing ACT treatment) human chondrocytes isolated from non-weight bearing area of the knee cartilage of patients undergoing ACT treatment, subcultured up to passage 2 (primary cells = passage 0), seeded onto hyaff-11 scaffold, maintained for 14 days in the presence of TGFbeta 1, chondrocytes obtained from normal donor 2
GSM413848
GPL570
3D-cultured chondrocytes from normal donor 3 human subcultured chondrocytes (passage 2) from normal donors maintained for 14 days in scaffold culture disease group: normal cell type: chondrocytes cell culture: 3-D ND_3_Chon_CHyaff_D14_133P human chondrocytes cultured in DMEM/F12 supplemented with L-ascorbic acid (0.025 mg/ml, gentamicin sulphate (50 mg/l), amphotericin B (250 µg/ml) and L-glutamine (2 mM; Gibco) and 10% human serum for 2 passages, 3D culture in Hyaff-11 scaffolds for 14 days maintained in DMEM high glucose supplemented with 5.0 µg/ml linoleic acid, insulin-transferrin-selenium-G, 1.0 mg/ml human serum albumin, 10 ng/ml transforming growth factor beta 1 (TGF-b1), 10-7 M dexamethasone , 14 µg/ml L-ascorbic acid and 1% penicillin-streptomycin; normal donor group (46-52 years, no pre-existing history of OA, macroscopically healthy cartilage, undergoing ACT treatment) human chondrocytes isolated from non-weight bearing area of the knee cartilage of patients undergoing ACT treatment, subcultured up to passage 2 (primary cells = passage 0), seeded onto hyaff-11 scaffold, maintained for 14 days in the presence of TGFbeta 1, chondrocytes obtained from normal donor 3
GSM413849
GPL570
3D-cultured chondrocytes from OA donor 1 human subcultured chondrocytes (passage 2) from OA donors maintained for 14 days in scaffold culture disease group: osteoarthritis cell type: chondrocytes cell culture: 3-D OA_1_Chon_CHyaff_D14_133P human chondrocytes cultured in DMEM/F12 supplemented with L-ascorbic acid (0.025 mg/ml, gentamicin sulphate (50 mg/l), amphotericin B (250 µg/ml) and L-glutamine (2 mM; Gibco) and 10% human serum for 2 passages, 3D culture in Hyaff-11 scaffolds for 14 days maintained in DMEM high glucose supplemented with 5.0 µg/ml linoleic acid, insulin-transferrin-selenium-G, 1.0 mg/ml human serum albumin, 10 ng/ml transforming growth factor beta 1 (TGF-b1), 10-7 M dexamethasone , 14 µg/ml L-ascorbic acid and 1% penicillin-streptomycin; OA donor group (60-64 years, symptoms of severe OA, undergoing total knee replacement, radiological evidence of OA, OA grade 2-3 according to Ahlbäck, and exhibiting a Mankin score above 3) human chondrocytes isolated from non-weight bearing area of the knee cartilage of patients undergoing ACT treatment, subcultured up to passage 2 (primary cells = passage 0), seeded onto hyaff-11 scaffold, maintained for 14 days in the presence of TGFbeta 1, chondrocytes obtained from OA donor 1
GSM413850
GPL570
3D-cultured chondrocytes from OA donor 2 human subcultured chondrocytes (passage 2) from OA donors maintained for 14 days in scaffold culture disease group: osteoarthritis cell type: chondrocytes cell culture: 3-D OA_2_Chon_CHyaff_D14_133P human chondrocytes cultured in DMEM/F12 supplemented with L-ascorbic acid (0.025 mg/ml, gentamicin sulphate (50 mg/l), amphotericin B (250 µg/ml) and L-glutamine (2 mM; Gibco) and 10% human serum for 2 passages, 3D culture in Hyaff-11 scaffolds for 14 days maintained in DMEM high glucose supplemented with 5.0 µg/ml linoleic acid, insulin-transferrin-selenium-G, 1.0 mg/ml human serum albumin, 10 ng/ml transforming growth factor beta 1 (TGF-b1), 10-7 M dexamethasone , 14 µg/ml L-ascorbic acid and 1% penicillin-streptomycin; OA donor group (60-64 years, symptoms of severe OA, undergoing total knee replacement, radiological evidence of OA, OA grade 2-3 according to Ahlbäck, and exhibiting a Mankin score above 3) human chondrocytes isolated from non-weight bearing area of the knee cartilage of patients undergoing ACT treatment, subcultured up to passage 2 (primary cells = passage 0), seeded onto hyaff-11 scaffold, maintained for 14 days in the presence of TGFbeta 1, chondrocytes obtained from OA donor 2
GSM413851
GPL570
3D cultured chondrocytes from OA donor 3 human subcultured chondrocytes (passage 2) from OA donors maintained for 14 days in scaffold culture disease group: osteoarthritis cell type: chondrocytes cell culture: 3-D OA_3_Chon_CHyaff_D14_133P human chondrocytes cultured in DMEM/F12 supplemented with L-ascorbic acid (0.025 mg/ml, gentamicin sulphate (50 mg/l), amphotericin B (250 µg/ml) and L-glutamine (2 mM; Gibco) and 10% human serum for 2 passages, 3D culture in Hyaff-11 scaffolds for 14 days maintained in DMEM high glucose supplemented with 5.0 µg/ml linoleic acid, insulin-transferrin-selenium-G, 1.0 mg/ml human serum albumin, 10 ng/ml transforming growth factor beta 1 (TGF-b1), 10-7 M dexamethasone , 14 µg/ml L-ascorbic acid and 1% penicillin-streptomycin; OA donor group (60-64 years, symptoms of severe OA, undergoing total knee replacement, radiological evidence of OA, OA grade 2-3 according to Ahlbäck, and exhibiting a Mankin score above 3) human chondrocytes isolated from non-weight bearing area of the knee cartilage of patients undergoing ACT treatment, subcultured up to passage 2 (primary cells = passage 0), seeded onto hyaff-11 scaffold, maintained for 14 days in the presence of TGFbeta 1, chondrocytes obtained from OA donor 3
 
 
Make groups for comparisons
(2 groups will be compared at a time)
Select GSMs and click on "Add groups"
Enter the group name here:


Select expression type
Transcripts profile based on;
A. Differential status (Up/Down regulation)
B. Absolute calls (Transcribed/Not-detected)
 
Filter results by number of probes